

Application of the anthraquinone drug rhein as axial ligand in bifunctional Pt(IV) complexes to obtain antiproliferative agents against human glioblastoma cells

Elisabetta Gabano,^a Marzia Bruna Gariboldi,^b Giulia Caron,^c Giuseppe Ermondi,^c Emanuela Marras,^b Maura Vallaro,^c Mauro Ravera^{a,*}

^a *Dipartimento di Scienze e Innovazione Tecnologica, Università del Piemonte Orientale, Viale Michel 11, 15121 Alessandria, Italy.*

^b *Dipartimento di Biotecnologie e Scienze della Vita (DBSV), Università dell'Insubria, via Dunant 3, Varese, Italy.*

^c *CASSMedChem, Dipartimento di Biotecnologie Molecolari e Scienze per la Salute, Università di Torino, Via Quarello 15, 10135 Torino, Italy.*

SUPPLEMENTARY MATERIAL

Content

- Figure S1** Sketch of the compounds under investigation and numbering scheme for NMR assignment.
- Figures S2-S7** ESI-MS, ¹H, ¹³C, ¹⁹⁵Pt, [¹H, ¹H] COSY and [¹H, ¹³C] HSQC NMR spectra of **1**.
- Figures S8-S13** ESI-MS, ¹H, ¹³C, ¹⁹⁵Pt, [¹H, ¹H] COSY and [¹H, ¹³C] HSQC NMR spectra of **2**.
- Figures S14-S19** ESI-MS, ¹H, ¹³C, ¹⁹⁵Pt, [¹H, ¹H] COSY and [¹H, ¹³C] HSQC NMR spectra of **3**.
- Figure S20** Solution behavior of the **1-3** complexes in RPMI 1640 cell culture medium with CH₃OH as cosolvent.
- Figure S21-S23** ESI-MS spectra of ¹⁵N-labeled **1-3**.
- Figure S24-S25** [¹H, ¹⁵N] HSQC NMR spectrum of ¹⁵N-**1** before and after reduction with cytosol.
- Figure S26-S27** [¹H, ¹⁵N] HSQC NMR spectrum of ¹⁵N-**2** before and after reduction with cytosol.
- Figure S28-S29** [¹H, ¹⁵N] HSQC NMR spectrum of ¹⁵N-**3** before and after reduction with cytosol.

* Corresponding author. E-mail address: mauro.ravera@uniupo.it




Figure S1. Sketch of the compounds under investigation and numbering scheme for NMR assignment used in the characterization of the complexes (see Experimental section). The assignment includes numbers and codes for the different portions of the molecules: Ac = acetate, AH = 7-aminoheptanoic acid, β A = β -alanine, R = **rhein**.




Figure S2. ESI-MS of **1**.




Figure S3. ¹H NMR spectrum of **1** (in DMSO-d₆).




Figure S4. ^{13}C NMR spectrum of **1** (in DMSO-d₆).




Figure S5. ^{195}Pt NMR spectrum of **1** (in DMSO-d₆).




Figure S6. [^1H , ^1H] COSY NMR spectrum of **1** (in DMSO- d_6).




Figure S7. [^1H , ^{13}C] HSQC NMR spectrum of **1** (in DMSO- d_6).




Figure S8. ESI-MS spectrum of **2**.




Figure S9. ¹H NMR spectrum of **2** (in DMSO-d₆). The signals of residual *N,N*-dimethylformamide are also visible (*).




Figure S10. ^{13}C NMR spectrum of **2** (in DMSO-d₆).




Figure S11. ^{195}Pt NMR spectrum of **2** (in DMSO-d₆).




Figure S12. [^1H , ^1H] COSY NMR spectrum of **2** (in DMSO-d₆).




Figure S13. [^1H , ^{13}C] HSQC NMR spectrum of **2** (in DMSO-d₆).




Figure S14. ESI-MS spectrum of **3** (in DMSO-d₆).




Figure S15. ¹H NMR spectrum of **3** (in DMSO-d₆).




Figure S16. ^{13}C NMR spectrum of **3** (in DMSO-d₆).




Figure S17. ^{195}Pt NMR spectrum of **3** (in DMSO-d₆).




Figure S18. [^1H , ^1H] COSY NMR spectrum of **3** (in DMSO-d₆).




Figure S19. [^1H , ^{13}C] HSQC NMR spectrum of **3** (in DMSO-d₆).




Figure S20. Solution behavior of the **1-3** complexes in RPMI 1640 cell culture medium with CH₃OH as cosolvent (10% v/v); final [Pt] = 0.1 mM. The reaction was monitored at 37 °C for 72 h by measuring the area of the RP-HPLC chromatographic peaks of the Pt complexes at the different time points (A). Data are normalized vs. the area at t = 0 (A₀).




Figure S21. ESI MS spectrum of ¹⁵N-1.




Figure S22. ESI MS spectrum of ¹⁵N-2.




Figure S23. ESI MS spectrum of ¹⁵N-3.




Figure S24. [^1H , ^{15}N] HSQC NMR spectrum of ^{15}N -**1** (in DMF/ D_2O / H_2O).




Figure S25. [^1H , ^{15}N] HSQC NMR spectrum of ^{15}N -1 upon reduction with cytosol.




Figure S26. [^1H , ^{15}N] HSQC NMR spectrum of ^{15}N -**2** (in DMF/ D_2O / H_2O).




Figure S27. [^1H , ^{15}N] HSQC NMR spectrum of ^{15}N -2 upon reduction with cytosol.




Figure S28. [^1H , ^{15}N] HSQC NMR spectrum of ^{15}N -**3** (in DMF/ D_2O / H_2O).




Figure S29. [^1H , ^{15}N] HSQC NMR spectrum of ^{15}N -3 upon reduction with cytosol.